24/7 BIOPHARMA | NEWSLETTER MAY 2026

Quotient Sciences Advances AI-Designed Drug Product into Clinical Development Quotient Sciences announced the successful initiation of a clinical study evaluating a novel drug product developed using artificial intelligence (AI) – a landmark achievement highlighting the growing potential of AI to guide formulation design and accelerate drug development. The pioneering Phase I clinical study was initiated at Quotient Sciences’ UK facility following approval from the Medicines and Healthcare products Regulatory Agency (MHRA). The study will assess the safety and pharmacokinetics of an oral solid dose formulation in healthy volunteers. A key objective of the study is to validate the use of AI in drug product development, demonstrating the potential of AI to accelerate formulation design... READ MORE DCAT https://youtu.be/Ut1LAt9MGKg

RkJQdWJsaXNoZXIy MjY2OTA4MA==